Steering the Industry through Tough Times
This article was originally published in SRA
Executive Summary
European Union member state ministers have clearly sidelined the information to patients section of the pharmaceutical package that is making its way through the European legislative process1,2. It appears that the main factor preventing its progression is an overriding concern that it could lead to direct-to-consumer advertising. The European industry has stressed that DTC advertising, which exists in the US, is something it has never wanted to be introduced. Also, it would have been prepared to have the information that it supplies vetted by an independent third party.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.